pharmaceutical-investing Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia
pharmaceutical-investing Moleculin’s Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa
pharmaceutical-investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
pharmaceutical-investing Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
pharmaceutical-investing Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery
Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound
